PascualLab voluntarily recalls some calcium supplements
MANILA, Philippines - Around 164 boxes of calcium supplement brand CalChews (chocolate flavor) have been voluntarily recalled by a subsidiary of Pascual Laboratories Inc.
Pascual Consumer Healthcare Corp. ordered the voluntary recall of the specific batch of CalChews after finding traces of microbial presence in certain stocks.
"In keeping with Pascual Consumer Healthcare Corp.'s commitment to serve with integrity and to guarantee the quality of our products, we are implementing, as a precautionary measure, the voluntary product recall of CalChews chocolate variant bearing the lot numbers 382BWA and 382BWB, due to findings of microbial presence," Ricky Rivera, president of Pascual Consumer Healthcare, said, in a statement.
The company on Monday notified the Food and Drug Administration of the product recall.
Based on records, 164 boxes of these lots have been distributed to 17 trade accounts.
CalChews is manufactured in the US, and packed, labelled and distributed by PascualLab.
PascualLab said its quality control procedures have detected the microbial presence in the affected lots of CalChews chocolate variant. After detecting microbial presence, it stopped the labelling and release of all stocks of CalChews from its Balagtas plant.
PascualLab said it has also informed the US manufacturer of CalChews of its findings based on local tests conducted, and will begin a comprehensive investigation on the matter.
Test results to date indicate that the microbial contamination concern appears to be limited to the stocks with lot numbers 382BWA and 382BWB, hence the selective voluntary recall.
Tests on the other lots of CalChews currently available in the market show that these are compliant to product quality specifications.
"We would like to assure the public that we will be even more vigilant with the quality of our products, as we continue to reinforce our current practices on inspections, sampling and checking to the best of our abilities," Rivera said.
For questions, or clarifications, the company advised the public to contact Mr. James Yaranon, PascualLab’s Pharmacovigilance Officer, through contact number 0917-7271304 or email [email protected].